Mineralys Therapeutics 2026 shareholder vote results
Mineralys Therapeutics, Inc. held its 2026 annual stockholder meeting on May 21, 2026, where two proposals were voted on.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Mineralys Therapeutics, Inc. held its 2026 annual stockholder meeting on May 21, 2026, where two proposals were voted on. Stockholders elected three Class III directors to three-year terms ending at the 2029 annual meeting and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Both proposals received the requisite affirmative vote of the company’s common stockholders.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Director Akkaraju votes for: 40,667,555 shares
Director Karydas votes for: 66,626,766 shares
Auditor ratification votes for: 72,648,272 shares
+2 more
5 metrics
Director Akkaraju votes for
40,667,555 shares
Votes for Srinivas Akkaraju, M.D., Ph.D. as Class III director
Director Karydas votes for
66,626,766 shares
Votes for Daphne Karydas as Class III director
Auditor ratification votes for
72,648,272 shares
For ratifying Ernst & Young LLP for fiscal year ending December 31, 2026
Auditor ratification votes against
9,516 shares
Against ratifying Ernst & Young LLP
Auditor ratification abstentions
27,265 shares
Abstain votes on auditor ratification
Key Terms
broker non-votes, independent registered public accounting firm, emerging growth company, definitive proxy statement
4 terms
broker non-votes financial
"Name | For | Withhold | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
definitive proxy statement regulatory
"Each Proposal is described in detail in the Company’s definitive proxy statement for the Annual Meeting"
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Mineralys Therapeutics (MLYS) stockholders vote on at the 2026 annual meeting?
Stockholders voted on electing three Class III directors and ratifying Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. Both proposals were approved by the holders of common stock.
Were Mineralys Therapeutics (MLYS) director nominees elected at the 2026 annual meeting?
Yes. Three nominees were elected as Class III directors to serve three-year terms expiring at the 2029 annual meeting of stockholders. Each director received the required affirmative votes from holders of the company’s common stock present or represented.
Which auditing firm did Mineralys Therapeutics (MLYS) stockholders ratify for fiscal 2026?
Stockholders ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification proposal received the necessary affirmative vote from common stockholders.
Did all Mineralys Therapeutics (MLYS) proposals at the 2026 annual meeting pass?
Yes. Both the election of three Class III directors and the ratification of Ernst & Young LLP as independent auditor were approved. Each proposal obtained the requisite affirmative vote from stockholders entitled to vote at the meeting.
Where can Mineralys Therapeutics (MLYS) investors find more detail on the 2026 proposals?
Further details on each proposal are contained in the company’s definitive proxy statement for the 2026 annual meeting, which was filed with the Securities and Exchange Commission on April 8, 2026 and describes the matters submitted to stockholders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates